Phase I dose escalation study of bortezomib in combination with lenalidomide in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).
Philip C. Amrein
No relevant relationships to disclose
Eyal C. Attar
No relevant relationships to disclose
Amir Tahmasb Fathi
No relevant relationships to disclose
Steven L McAfee
No relevant relationships to disclose
Martha Wadleigh
No relevant relationships to disclose
Daniel J. DeAngelo
No relevant relationships to disclose
David P. Steensma
No relevant relationships to disclose
Julia Foster
No relevant relationships to disclose
Richard M. Stone
Consultant or Advisory Role - Celgene
Donna S. Neuberg
No relevant relationships to disclose
Karen K. Ballen
No relevant relationships to disclose